Finland Sees Progress On Biosimilar Substitution Plans
Updated Proposals Reflect Industry Criticism; Parliamentary Approval Expected In Weeks
Updated plans to implement pharmacy-level biosimilar substitution in Finland have just been published by a parliamentary health committee ahead of expected formal approval within weeks, reflecting certain industry criticisms that have now been taken on board.
You may also be interested in...
The recent statement by the EMA and HMA affirming the interchangeability of biologics and biosimilars has given a boost to Europe’s biosimilars industry ahead of key legislative reforms, heard delegates to Medicines for Europe’s 18th Biosimilar Medicines Conference in Brussels.
The latest step towards biosimilar substitution taken by the French authorities has left stakeholders baffled by an unexplained shift in approach, including a change to the specific biologic molecules that have been selected as eligible for substitution.
Ahead of the Global Generics & Biosimilars Awards, which are this year being held on Wednesday 25 October at the Hotel Porta Fira in Barcelona, we reveal our final shortlist of entrants across all 14 categories.